CY1122522T1 - Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος - Google Patents

Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος

Info

Publication number
CY1122522T1
CY1122522T1 CY20191101162T CY191101162T CY1122522T1 CY 1122522 T1 CY1122522 T1 CY 1122522T1 CY 20191101162 T CY20191101162 T CY 20191101162T CY 191101162 T CY191101162 T CY 191101162T CY 1122522 T1 CY1122522 T1 CY 1122522T1
Authority
CY
Cyprus
Prior art keywords
sodium
multiple myeloma
arsenicode
meta
management
Prior art date
Application number
CY20191101162T
Other languages
English (en)
Inventor
Sang-Bong Lee
Yong-Jin Yang
Original Assignee
Kominox, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kominox, Inc. filed Critical Kominox, Inc.
Publication of CY1122522T1 publication Critical patent/CY1122522T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Luminescent Compositions (AREA)

Abstract

Μετα αρσενικώδες νάτριο για χρήση στην αγωγή του πολλαπλού μυελώματος.
CY20191101162T 2005-05-09 2019-11-06 Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος CY1122522T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05076071A EP1721615A1 (en) 2005-05-09 2005-05-09 Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
EP06732912A EP1885380B1 (en) 2005-05-09 2006-05-09 Sodium meta-arsenite for use in the treatment of metastatic neoplastic diseases
EP14166070.4A EP2762145A1 (en) 2005-05-09 2006-05-09 Sodium meta arsenite for use in the treatment of pain and/or inflammation associated with cancer
PCT/KR2006/001731 WO2006121280A1 (en) 2005-05-09 2006-05-09 Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment of urogenital cancer and its metastasis
EP11165670.8A EP2361628A1 (en) 2005-05-09 2006-05-09 Pharmaceutical compositions comprising of sodium meta-arsenite for use in the treatment of leukemia and lymphoma

Publications (1)

Publication Number Publication Date
CY1122522T1 true CY1122522T1 (el) 2021-01-27

Family

ID=35197739

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20121100940T CY1113475T1 (el) 2005-05-09 2012-10-10 Μετα-αρσενικωδες νατριο για χρηση στην αγωγη μεταστατικων νεοπλασματικων παθησεων
CY20191101162T CY1122522T1 (el) 2005-05-09 2019-11-06 Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20121100940T CY1113475T1 (el) 2005-05-09 2012-10-10 Μετα-αρσενικωδες νατριο για χρηση στην αγωγη μεταστατικων νεοπλασματικων παθησεων

Country Status (24)

Country Link
US (2) US20090011047A1 (el)
EP (5) EP1721615A1 (el)
JP (1) JP5026408B2 (el)
KR (3) KR101413731B1 (el)
CN (2) CN104758312A (el)
AR (1) AR054448A1 (el)
AU (1) AU2006244767B2 (el)
BR (1) BRPI0608716A2 (el)
CA (3) CA2608035C (el)
CY (2) CY1113475T1 (el)
DK (2) DK3067068T3 (el)
ES (2) ES2394264T3 (el)
HK (1) HK1109736A1 (el)
HU (1) HUE046029T2 (el)
IL (3) IL187220A (el)
LT (1) LT3067068T (el)
PL (2) PL3067068T3 (el)
PT (1) PT1885380E (el)
RU (1) RU2401662C2 (el)
SG (5) SG10201602555WA (el)
SI (2) SI1885380T1 (el)
TW (5) TWI522105B (el)
WO (1) WO2006121280A1 (el)
ZA (1) ZA200710559B (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8945505B2 (en) * 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
US20090246291A1 (en) * 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
US20120045520A1 (en) * 2008-08-21 2012-02-23 Sang Bong Lee Pharmaceutical composition comprising arsenite for the treatment of malignancy
KR101721009B1 (ko) * 2009-09-10 2017-03-29 코미녹스 인코포레이티드 암 줄기세포-표적 및 약물 내성 암 치료
JP2013505242A (ja) * 2009-09-18 2013-02-14 コミノックス・インコーポレイテッド 脳腫瘍を治療するための方法
EP2524226A1 (en) 2010-01-13 2012-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Promyelocytic leukemia protein as a redox sensor
CN103442705B (zh) * 2011-01-11 2015-11-25 巴塞尔大学 用于治疗癌症和免疫抑制的昔洛舍平与线粒体抑制剂的组合
WO2012131487A2 (en) * 2011-03-30 2012-10-04 Kominox, Inc. Compositions and methods for the treatment of cancer
KR101309844B1 (ko) * 2013-03-15 2013-09-23 박상채 항암 활성 증진용 한약재 및 이의 제조방법
RU2618405C1 (ru) * 2015-12-31 2017-05-03 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ определения продолжительности адъювантной химиотерапии при местно-распространенном колоректальном раке с метастазами в регионарные лимфоузлы после радикальных оперативных вмешательств
US10806768B2 (en) * 2016-05-26 2020-10-20 Stephen N. Pitcher Composition for promoting metallothionein production
EP3548044B1 (en) 2016-12-01 2023-09-20 Eupharma Pty Ltd Arsenic compositions
AU2019239671A1 (en) * 2018-03-22 2020-10-01 Komipharm International Australia Pty Ltd Pharmaceutical composition comprising meta arsenite and method of manufacture
WO2019234112A1 (en) * 2018-06-05 2019-12-12 Katholieke Universiteit Leuven Combination treatment of arsenic oxide and antiandrogens
KR20230019811A (ko) * 2020-02-16 2023-02-09 코미팜 인터내셔널 오스트레일리아 피티와이 엘티디 메타-아비산염을 이용하는 치료 방법
KR20220020633A (ko) * 2020-08-12 2022-02-21 이상봉 탈모방지 또는 발모촉진용 주사제 조성물
KR20220020637A (ko) * 2020-08-12 2022-02-21 이상봉 항암화학요법이나 방사선요법으로 인한 암 환자의 탈모증을 포함한 탈모증 환자에 대하여 탈모를 방지하고 발모를 촉진하는 메타아르세나이트의 염을 함유하는 경구 투여용 약학적 조성물
KR20220020635A (ko) * 2020-08-12 2022-02-21 이상봉 탈모방지 또는 발모촉진용 외용제 조성물
CN112336746A (zh) * 2020-10-23 2021-02-09 内蒙古科技大学包头医学院 一种膀胱癌灌注化疗药物及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
FR2431686A1 (fr) 1978-07-20 1980-02-15 Nestle Sa Soc Ass Tech Prod Mecanisme de dosage et d'equilibrage et machine de remplissage comprenant un tel mecanisme
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
KR930001917A (ko) * 1991-07-26 1993-02-22 김두석 악성 종양 치료제의 제조방법
CA2183547C (en) * 1994-02-18 2002-05-14 Tamara Vasilievna Vorobieva Compositions for treating defective cell functions
WO1999018798A1 (en) * 1997-10-15 1999-04-22 Polarx Biopharmaceuticals, Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
KR20010031938A (ko) 1997-11-10 2001-04-16 추후제출 삼산화비소 조성물을 생산하는 방법 및 삼산화비소 또는멜랄소프롤을 이용하여 암을 치료하는 방법
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
KR20020083678A (ko) * 2001-04-28 2002-11-04 주식회사 한국미생물연구소 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물
TW200408407A (en) 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
AU2002253713B2 (en) * 2002-04-10 2008-09-18 Kominox, Inc. Pharmaceutical composition comprising arsenite for the treatment of malignancy
KR100632250B1 (ko) * 2004-02-16 2006-10-11 정태호 비소 화합물을 유효성분으로 하는 항암제
US20060104292A1 (en) 2004-11-15 2006-05-18 Gupta Vivek G System and methods for supporting multiple communications interfaces with single client interface
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
US20090246291A1 (en) 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
KR101721009B1 (ko) 2009-09-10 2017-03-29 코미녹스 인코포레이티드 암 줄기세포-표적 및 약물 내성 암 치료

Also Published As

Publication number Publication date
TWI574692B (zh) 2017-03-21
CA2840609A1 (en) 2006-11-16
EP1721615A1 (en) 2006-11-15
SG177983A1 (en) 2012-02-28
SI1885380T1 (sl) 2013-01-31
AU2006244767B2 (en) 2011-06-16
KR20160035101A (ko) 2016-03-30
ES2394264T3 (es) 2013-01-30
SG10201405278SA (en) 2015-05-28
SI3067068T1 (sl) 2020-02-28
US20160199411A1 (en) 2016-07-14
IL229975A0 (en) 2014-01-30
WO2006121280A1 (en) 2006-11-16
TWI539957B (zh) 2016-07-01
EP1885380B1 (en) 2012-07-11
IL187220A (en) 2014-11-30
US11464859B2 (en) 2022-10-11
AU2006244767A1 (en) 2006-11-16
CA2608035C (en) 2015-02-17
SG10201602555WA (en) 2016-05-30
TWI522105B (zh) 2016-02-21
JP2008546640A (ja) 2008-12-25
CA2926846C (en) 2019-04-02
SG10202100785PA (en) 2021-02-25
CA2608035A1 (en) 2006-11-16
CN101277707A (zh) 2008-10-01
PL1885380T3 (pl) 2013-02-28
AR054448A1 (es) 2007-06-27
ZA200710559B (en) 2008-10-29
KR20080030559A (ko) 2008-04-04
CY1113475T1 (el) 2016-06-22
JP5026408B2 (ja) 2012-09-12
EP3067068A1 (en) 2016-09-14
PL3067068T3 (pl) 2020-08-10
EP1885380A1 (en) 2008-02-13
SG175633A1 (en) 2011-11-28
ES2754372T3 (es) 2020-04-17
EP2762145A1 (en) 2014-08-06
CA2926846A1 (en) 2006-11-16
TW201500046A (zh) 2015-01-01
IL187220A0 (en) 2008-02-09
EP1885380A4 (en) 2009-02-18
TWI386214B (zh) 2013-02-21
DK1885380T3 (da) 2012-10-22
RU2401662C2 (ru) 2010-10-20
TW201540306A (zh) 2015-11-01
TW201615200A (zh) 2016-05-01
IL244728A0 (en) 2016-04-21
EP2361628A1 (en) 2011-08-31
RU2007145489A (ru) 2009-06-20
US20090011047A1 (en) 2009-01-08
CN104758312A (zh) 2015-07-08
EP3067068B1 (en) 2019-08-14
KR20150085122A (ko) 2015-07-22
HUE046029T2 (hu) 2020-01-28
PT1885380E (pt) 2012-10-11
IL229975A (en) 2017-12-31
HK1109736A1 (en) 2008-06-20
DK3067068T3 (da) 2019-11-18
KR101413731B1 (ko) 2014-07-10
TW201302208A (zh) 2013-01-16
TW200716144A (en) 2007-05-01
CA2840609C (en) 2016-08-16
BRPI0608716A2 (pt) 2010-12-07
LT3067068T (lt) 2019-12-10

Similar Documents

Publication Publication Date Title
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
EA201000888A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и 2-фенилциклогексан-1,3,5-трионы в качестве гербицидов
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
TW200716624A (en) Compounds for modulating TRPV3 function
GB2436983A (en) Information access with usage-driven metadata feedback
EA200802213A1 (ru) Способы лечения заболеваний крови
EA201170521A1 (ru) Новые соединения
EP1904964A4 (en) HANDLING MANAGEMENT SYSTEM
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
RS52784B (en) They're TANATE RAZAGILINA
ATE488232T1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
UY3493Q (es) Esponja
NO20082191L (no) Forbindelser
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
GB2437009A (en) Ranking system
ME01459B (me) Postupak za doziranje medikamenata
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
EA201000258A1 (ru) Новые гербициды
EA201000069A1 (ru) Новые гербициды
SE0301650D0 (sv) Novel compounds
CR11368A (es) Forma cristalina 1 de 2- ( (r)-2-metilpirrolidin-2-il) -1h-benzimidazol-4-carboxamida